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ABSTRACT
Pancreatic cystic lesions can be benign,
premalignant or malignant. The recent increase in
detection and tremendous clinical variability of
pancreatic cysts has presented a signiﬁcant
therapeutic challenge to physicians. Mucinous cystic
neoplasms are of particular interest given their
known malignant potential. This review article
provides a brief but comprehensive review of
premalignant pancreatic cystic lesions with advanced
endoscopic ultrasound (EUS) management
approaches. A comprehensive literature search was
performed using PubMed, Cochrane, OVID and
EMBASE databases. Preneoplastic pancreatic cystic
lesions include mucinous cystadenoma and
intraductal papillary mucinous neoplasm. The 2012
International Sendai Guidelines guide physicians in
their management of pancreatic cystic lesions. Some
of the advanced EUS management techniques
include ethanol ablation, chemotherapeutic
(paclitaxel) ablation, radiofrequency ablation and
cryotherapy. In future, EUS-guided injections of
drug-eluting beads and neodymium:yttrium
aluminum agent laser ablation is predicted to be an
integral part of EUS-guided management
techniques. In summary, International Sendai
Consensus Guidelines should be used to make a
decision regarding management of pancreatic cystic
lesions. Advanced EUS techniques are proving
extremely beneﬁcial in management, especially in
those patients who are at high surgical risk.
BACKGROUND
Cystic lesions of the pancreas span a wide clin-
ical spectrum and include inﬂammatory pseu-
docysts, non-mucinous (serous cystadenomas,
solid pseudopapillary neoplasms) and mucinous
cysts (mucinous cystadenomas (MCAs), mucin-
ous cystadenocarcinomas and intraductal papil-
lary mucinous neoplasms (IPMNs)). Ductal
adenocarcinoma and neuroendocrine tumors
are often included in cyst classiﬁcation
schemes, though these are largely solid pancre-
atic tumors that have undergone degenerative
cystic change.1
Pancreatic cystic neoplasms represent benign,
premalignant, and malignant lesions. The
prevalence of pancreatic cysts in asymptomatic
adults varies depending on the screening
modality, ranging from 0.2% on the ultrasound
to ∼20% on MRI.2 3 Higher rates are reported
in the elderly and Asians.4 Generally, size
≥3 cm, presence of a solid component, dilated
pancreatic duct, growth of >2 mm/year, pres-
ence of mural nodules, and suggestive cytology
or biochemical analysis on ﬁne needle aspir-
ation (FNA) are associated with increased
malignant potential.5–8
Major management approaches include sur-
gical resection, endoscopic techniques, and sur-
veillance. Surgical resection or enucleation has
long been considered the gold standard for
management of premalignant and malignant
lesions. The decision to resect a lesion is based
on several factors: the presence or absence of
symptoms, location of the lesion, probability of
malignancy, and surgical risk of the patient.
Further tools such as the Sendai International
Consensus Guidelines have been developed to
guide physicians in their decision-making.9
Surgical management is not without morbidity.
Perioperative complication rates range between
20% and 40% and mortality approaches 2%,
even in robust surgical candidates.10–13 As such,
endoscopic techniques have posed an attractive
alternative to classic surgical interventions, par-
ticularly in patients with comorbidities or
asymptomatic, indeterminate cystic lesions.
The increase in detection and tremendous
clinical variability of pancreatic cysts has pre-
sented a signiﬁcant therapeutic challenge to
physicians. Mucinous cystic neoplasms are of
particular interest due to their malignant poten-
tial. This review article focuses on the patho-
genesis as well as the management of mucinous
cystic neoplasms, due to their malignant
potential.
Mucinous cystic neoplasms
Mucinous cystic neoplasms of the pancreas are
cystic neoplasms which are composed of
columnar, mucin-producing epithelium, sup-
ported by ovarian-type stroma. Clinically, most
mucinous cystic neoplasms are discovered as
incidental ﬁndings during imaging for another
indication. Mucinous cystic neoplasms can
compress adjacent organs and produce symp-
toms if they are large in size. These lesions are
becoming an important point of discussion due
to their potential for malignant transformation.
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Mucinous cystic neoplasms can be further subdivided
into three categories: MCAs, mucinous adenocarcinomas,
and IPMNs.
MCA and mucinous adenocarcinoma
MCAs are premalignant and may progress to invasive
mucinous cystadenocarcinoma.14 In one series, 10% of
MCAs progressed to invasive adenocarcinoma at the time
of resection.15 16 These macrocystic lesions are found
mostly in women and have a propensity to form in the
body and tail of the pancreas.17 18 MCAs are unilocular
and typically do not communicate with the pancreatic duct.
Lined by mucin-secreting cells, they often contain a highly
cellular ‘ovarian’ stroma. Genetic mutations, including
K-ras mutations, have been associated with the develop-
ment of these lesions19 (ﬁgures 1 and 2).
Intraductal papillary mucinous neoplasm
IPMNs arise from the mucin-producing cells within the
pancreatic duct. They are also considered to be premalig-
nant and may progress to invasive adenocarcinoma. IPMNs
are further classiﬁed into three types based on their site of
origin: main duct (MD)-IPMN, branch duct (BD)-IPMN,
and mixed type (arising from both ducts).17 MD-IPMNs
are more likely to be malignant with at least one-third har-
boring invasive cancer at the time of resection. IPMNs
occur more commonly in elderly men and have a predilec-
tion for the head of the pancreas. Unlike MCAs, these
lesions communicate with the pancreatic duct. The charac-
teristic appearance on imaging or gross pathological evalu-
ation is pancreatic ductal dilation secondary to papillary
tumor growth. As in MCAs, the K-ras mutation has also
been implicated in the development of IPMNs.1
DIAGNOSTIC APPROACHES
While most patients with pancreatic cystic lesions are
asymptomatic, a small minority of patients may present
with non-speciﬁc symptoms including recurrent abdominal
discomfort, nausea, vomiting, and early satiety. Moreover,
symptoms such as weight loss, jaundice, steatorrhea, and
diabetes are more concerning and may be thought to
herald malignancy. Physical examination is likely to be
unrevealing, though in some cases, clinicians may note
jaundice or a palpable abdominal mass. Given the limita-
tions of a careful history and physical examination, radio-
graphic and endoscopic imaging techniques have been
employed to better characterize cystic lesions. The follow-
ing is a detailed discussion of the imaging modalities
available.
CT scan
CTscan is the most widely used initial imaging modality for
diagnosis and provides detailed images of the pancreas and
surrounding structures. Radiographic ﬁndings often reveal
pathognomonic features sufﬁcient for an accurate diagnosis
and importantly aid in distinguishing malignant neoplasms.
For example, detection of peripheral calciﬁcations or a
mural nodule by CT scan in a suspicious mucinous cystic
neoplasm (MCN) is highly suggestive of malignancy. In a
study performed by Le Baleur Y et al,20 no malignant MCN
had a diameter <40 mm. Thus, a diameter of <40 mm is
associated with low risk of malignancy (ﬁgures 3 and 4).
Figure 1 Gross appearance of a mucinous cystic lesion of the
pancreas.
Figure 2 Endoscopic ultrasound of a malignant mucinous lesion
with a mass ﬁlling the cystic space. The outer wall of the cyst is
indicated by the white arrow.
Figure 3 Contrast-enhanced CT scan showing mucinous
cystadenoma. A large cystic tumor with small cysts clustered at its
periphery (arrow). (Adapted with permission from: Kim YH
et al).68
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MR cholangiopancreatography
MR cholangiopancreatography (MRCP) has gained popu-
larity because it allows for detailed visualization of the pan-
creatic ductal system and surrounding parenchyma without
radiation exposure and invasive techniques. When applied
to pancreatic cystic neoplasms, MCRP may aid in the iden-
tiﬁcation of a ductal connection, small BD cysts or in the
estimation of MD involvement. These factors inﬂuence
diagnostic accuracy, cancer risk stratiﬁcation and manage-
ment strategies. Thus, MRCP use is very beneﬁcial in all
patients with IPMNs21 (ﬁgure 5).
Endoscopic ultrasound with FNA
When clinical and radiological indices are inadequate for
reliable identiﬁcation of pancreatic cystic structures, endo-
scopic ultrasound (EUS) in conjunction with FNA may be
employed to provide valuable diagnostic information.
Endoscopic imaging allows for detection of small lesions
and may also yield staging information via examination of
the surrounding vasculature. The addition of FNA
improves diagnostic accuracy via analysis of molecular
markers within the cystic ﬂuid itself. Cystic ﬂuid analysis
should include tumor markers such as carcinoembryonic
antigen (CEA) as well as amylase levels and careful cyto-
logical examination (ﬁgure 6).
Cystic ﬂuid CEA levels are of particular interest. High
CEA levels do not distinguish benign from malignant cysts
and are not predictive of disease progression;22 however,
studies have shown that higher CEA levels are associated
with mucinous cysts. In fact, a CEA level of 192 ng/mL has
a sensitivity approaching 80% for diagnosis.23 24 Amylase
levels are helpful in excluding pancreatic pseudocysts.
A ﬂuid amylase concentration of <250 U/L indicates low
risk of a pseudocyst. High pancreatic cyst ﬂuid amylase
values occur in pseudocysts and some mucin-producing
cystic neoplasms; thus, they are non-speciﬁc. Cytological
evaluation is the most important method in distinguishing
benign from malignant cysts.22–25 In recent years, DNA
analysis of cystic ﬂuid is becoming a point of interest. A
study performed by Nikiforova and colleagues showed that
K-ras mutations are highly speciﬁc (100%) but not very
sensitive (54%) for detection of mucinous differentiation
of pancreatic cysts. K-ras mutation had a sensitivity of 67%
for IPMNs and 14% for MCNs.26
Needle-based confocal laser endomicroscopy
Needle-based confocal laser endomicroscopy (nCLE) is a
new diagnostic approach applied via EUS. It involves real-
time imaging at the microscopic level using a sub-mm
probe which can be introduced through an FNA needle.
Figure 5 MR cholangiopancreatogram showing a lesion
suspicious for IPMN. Image shows a cystic, grape-like pancreatic
lesion. It is not clear whether there is a communication of the
mass and the pancreatic duct. Endoscopic retrograde
cholangiopancreatography (ERCP) would be useful in this
situation. (Adapted with permission from: Kim YH, et al.)68 IPMN,
intraductal papillary mucinous neoplasm.
Figure 6 Cytology slide of IPMN aspirate from EUS-FNA. An
intact cluster of moderately atypical epithelial cells with a single
residual mucin vacuole. Even small numbers of such atypical cells
warrant a suspicion of carcinoma. EUS, endoscopic ultrasound;
FNA, ﬁne needle aspiration; IPMN, intraductal papillary mucinous
neoplasm.
Figure 4 Contrast-enhanced CT scan showing branch duct IPMN.
A cystic lesion can be seen with a markedly dilated side branch
duct with wall thickening (arrow). (Adapted with permission from:
Kim YH et al.)68 IPMN, intraductal papillary mucinous neoplasm.
Review
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Napoleon and colleagues proposed new nCLE criteria for
characterization of pancreatic cystic lesions (mucinous
cystic neoplasm, cystic neuroendocrine neoplasms, pseuo-
docyst) based on histological correlation in a multicenter
study. Histologically, mucinous cystic neoplasms consist of
two distinct components: mucin-producing epithelium and
ﬁbrous tissue containing stroma composed of densely
packed spindle cells with some large blood vessels. On
nCLE, stroma was not clearly seen and the epithelial
border was seen as a gray band. Histologically, a pseudocyst
is seen as a ﬁbroinﬂammatory tissue around necrotic adipo-
cytes. On nCLE, a pseudocyst appears as a mixture of gray
and black particles of various sizes (10–40 mm). These par-
ticles represent inﬂammatory cells. A cystic neuroendocrine
neoplasm is histologically characterized by a neoplastic
monomorphic cell proliferation with variable organization
and cellular structure. The cell arrangement can be trabecu-
lar, diffuse or nested. Fibrotic stroma surrounds these cellu-
lar arrangements. On nCLE, dark irregular clusters of
compact cells representing neoplastic cells were seen which
were surrounded by gray colored stroma.
Results showed an overall accuracy of 94% for detection
of mucinous cystic lesions. Accuracy was found to be 87%
for characterization of pseudocysts.27 Nakai and colleagues
also assessed the diagnostic yield of combined nCLE and
cystoscopy for diagnosis of pancreatic cystic neoplasms.
Mucin on cystoscopy and papillary projections or black
rings on nCLE were found as characteristic features of
MCNs. This study described that when used alone, EUS
had a sensitivity of 53% and speciﬁcity of 67% for diagno-
sis of MCNs. When nCLE was used for diagnosis, sensitiv-
ity increased to 80% and speciﬁcity to 100%. Use of
cytology further improved sensitivity to 90%. Combined
use of nCLE and cystoscopy for diagnosis of MCNs pro-
duced results with 100% sensitivity and speciﬁcity.28
MANAGEMENT GUIDELINES
The 2012 Sendai International Consensus Guidelines were
released to guide physicians in their management of MCNs
and IPMNs. They recommend CT or MRCP for all cysts
≥1 cm. On the basis of these imaging techniques, patients
may be classiﬁed into one of two groups, high-risk stigmata
or worrisome features. High-risk stigmata include evidence
of an enhanced solid component of cysts, MD≥10 mm or
the presence of obstructive jaundice. Cysts with high-risk
stigmata should be resected in patients medically ﬁt for
surgery. In these patients, EUS is considered optional, but
may provide useful information preoperatively. Worrisome
features include but are not limited to cysts ≥3 cm, thick-
ened or enhanced cyst walls, MD size between 5 and
9 mm, and abrupt change in appearance and lymphadenop-
athy. EUS is subsequently recommended for all cysts with
worrisome features or for cysts >3 cm without these fea-
tures. EUS conﬁrmation of a mural nodule, MD involve-
ment or suspicious cytology is an indication for surgical
resection. Additionally, EUS can be considered in smaller
cysts without worrisome features but is not required.9
ADVANCED EUS MANAGEMENT APPROACHES
Ethanol ablation
Ablative ethanol therapy of cystic lesions has long been
regarded as a safe, effective and minimally invasive
management strategy, particularly when applied to hepatic,
renal, splenic, endometrial and thyroid cysts.29–36 For pan-
creatic cysts, this therapeutic option poses an attractive
alternative to classic surgical approaches, especially in those
patients with numerous preoperative comorbidities.
Ethanol is an inexpensive, low-viscosity, and widely avail-
able agent thought to induce cell membrane lysis, protein
denaturation, and vascular occlusion within minutes of
injection.37–39 Furthermore, when applied speciﬁcally to
pancreatic cystic lesions, the ethanol injection is thought to
reduce the risk of neoplasm by eliminating the source of
neoplasia, the cyst epithelium.40
Ethanol ablation is best performed by an experienced
endoscopist given the complex morphology of most pan-
creatic cysts. Pancreatic cysts are visualized using either a
radial scanning echoendoscope or a curvilinear array
echoendoscope. Cyst aspiration often occurs via a transgas-
tric or transduodenal approach and may be challenging,
particularly in cases of mucinous cysts given the viscous
nature of the aspirate. Evacuation of cyst ﬂuid provides
useful diagnostic information, creates space within the
cavity for the ablative agent and increases the surface area
of exposure to the ablative agent.41 After subtotal evacu-
ation, ethanol is injected and the cyst cavity is lavaged for
3–5 min, alternately ﬁlling and emptying. The concentra-
tion of ethanol varies, sometimes approaching 99%
depending on the endoscopist’s preference, and does not
appear to correlate with successful cyst resolution. At the
end of the lavage, the injected ethanol is mostly evacuated,
leaving only enough solution to outline the cyst cavity.
Care is taken throughout the procedure to ensure that the
needle tip is maintained within the cyst, to avoid parenchy-
mal injury or a leak in the wall. Once the procedure is
complete, the needle is removed from the cyst cavity.42
This algorithm becomes more complex when applied to
morphologically complex cysts, deﬁned as larger, thick
walled, multiloculated cysts.39 42 In these instances, a single
needle pass may not be sufﬁcient to provide adequate deliv-
ery of the ablative agent and the angle of introduction
should be optimized such that the maximum number of
locules are traversed.39 42 Even one missed locule may
result in cyst regeneration and treatment failure.
Procedural success has been well documented in the lit-
erature with overall resolution on imaging ranging from
33% to 38% at a follow-up period of 3–13 months.40 42 In
the largest multicenter, randomized, controlled, double-
blind study examining this subject matter, DeWitt and col-
leagues compared EUS-guided saline lavage to ethanol
lavage. They concluded that ethanol lavage resulted in a
greater decrease in cyst surface area and noted overall
CT-deﬁned resolution in 33% of patients at 3–4 months
after ablation.42 Concerns related to long-term procedural
success prompted DeWitt and colleagues to perform a sub-
sequent longitudinal evaluation of patients from the ori-
ginal study cohort. All nine patients with initial CT-deﬁned
resolution demonstrated no evidence of cyst recurrence on
repeat cross-sectional imaging at a median of 26 months
postablation.42 The results of this study suggest a durable
ablative response, effectively reducing the likelihood of cyst
reaccumulation and subsequent malignant transformation.
Park and colleagues demonstrated that the success rate of
ethanol ablation was different depending on cystic ﬂuid
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analysis (serous cystic neoplasm, 58%; mucinous cystic
neoplasm, 50%; IPMN, 11%; uncategorized cysts, 39%;
p<0.0001). On the basis of these results, ethanol ablation
produced disappointing results for treatment of IPMNs.43
Complications are uncommon and occur in some cases,
most commonly abdominal pain (18%) and pancreatitis
(3%).43 Pancreatitis may occur in the presence of a commu-
nication between the cyst and main pancreatic duct. In this
instance, ﬂow of the ablative agent may traverse the main
pancreatic duct, resulting in local inﬂammation as well as a
diminished ablative effect. Additionally, intracystic bleeding
has been reported in rare cases. Interestingly, a risk of clin-
ical ethanol intoxication also exists and has been documen-
ted in patients undergoing ethanol ablation of thyroid
cysts.44
Ablation with chemotherapeutic agents
A second ablative agent, paclitaxel, has been applied in the
management of pancreatic cystic neoplasms as well as in
tumors of the lung and brain.33 34 Paclitaxel is a commonly
used chemotherapeutic drug that works by inhibiting cell
processes that are dependent on microtubules, resulting in
cessation of cell division and induction of apoptosis. This
agent is hydrophobic and highly viscous, though its consist-
ency varies somewhat depending on the composition of its
co-solvent.45 A localized, rather than systemic, application
of paclitaxel has gained signiﬁcant favor, theoretically min-
imizing the toxicities of therapy while also increasing thera-
peutic concentrations within the cyst itself.46
In practice, paclitaxel and ethanol are thought to have a
synergistic ablative effect; thus, the combined use of these
two agents has been well described in the literature. Ethanol
lavage causes distortion of the cyst epithelial lining and
paclitaxel exerts secondary tumorous inhibition on the
injured tissue.34 42 47 The technique applied is similar to the
methods described above for ethanol ablation. Ethanol is
ﬁrst injected into a collapsed cyst, followed by a 3–5 min
lavage of the aspirate. The ethanol solution is subsequently
reaspirated and paclitaxel is injected into the empty cyst
cavity. The viscosity of the solution is thought to be of
mixed utility, reducing the risk of leakage through the punc-
ture site but also complicating the injection technique
itself.45 The needle is retrieved and the chemotherapeutic
agent remains within the cyst to exert its effect. A study
showed that complete resolution was achieved in 62% of
patients with a 2-year follow-up.41 In 2014, DeWitt and col-
leagues published a study showing a combined management
approach with ethanol and paclitaxel. Their results demon-
strated complete response in 50%, partial response in 25%
and a persistent cyst in 25% of patients. Adverse events
included abdominal pain in 13%, pancreatitis in 10%, peri-
tonitis in 3% and gastric wall cyst in 3%.48
Radiofrequency ablation
Radiofrequency ablation (RFA) is a well-established proced-
ure that has been applied to cystic lesions of the kidney,
thyroid, and pancreas, among others.49 50 Under endo-
scopic guidance, this technique allows targeted delivery of
electrical therapy, producing initial coagulative necrosis and
eventual ﬁbrotic changes in surrounding tissues.49
RFA uses a high-frequency (460–500 kHz) alternating
current that is delivered to a targeted lesion through a thin
needle which is inserted through the working channel of
an endoscope. This needle is electrically insulated except
for its terminal 1–3 cm. A current produces resistive fric-
tion in the tissue that is converted into heat, similar to the
way heat is generated from an electrical resistor in a circuit.
The current is completed with grounding pads placed on
the patient’s back and thighs. RFA can predictably produce
an ablation area of 3 cm at a single application, so cystic
lesions >3 cm may require more than one deployment of
the needle electrode.51 This technology has only recently
been adopted by endoscopists; thus, efﬁcacy data are
limited. Initial studies demonstrated that this technology is
feasible, effective and safe when applied to the porcine
pancreas.51 Pai and colleagues used RFA ablation for man-
agement of pancreatic cystic lesions in six patients.
Postprocedural imaging 3–6 months after treatment found
complete resolution of the cystic lesion in two patients and
48.4% reduction in the size of the cystic lesion in three
patients. No major complications were observed within
48 hours of the procedure. Two patients reported abdom-
inal pain.52
The application of RFA in unresectable pancreatic cancer
both in human and animal models demonstrates signiﬁcant
morbidity associated with its use.53 54 Complications such
as pancreatitis, perforation, or thermal injury to the bile duct,
pancreatic parenchyma, and vessels occurred.53 54 Cooling of
adjacent tissue and real-time visualization of the target and
surrounding structures has reduced procedure-related compli-
cations54–57 (ﬁgure 7).
Cryotherapy
Cryotherapy may also be applied to pancreatic cystic neo-
plasms and has demonstrated utility in neoplasms of the
liver, prostate, lung and breast.58 This technology is gaining
increasing popularity, particularly when used with adjunct-
ive therapies such as irradiation, chemotherapeutic drugs,
apoptotic promoters and immunological agents.58 59 In
contrast to the thermal injury generated via RFA, cryother-
apy induces damage via extreme cold produced by the
application of liquid nitrogen or argon gas. In vitro studies
on cancer cells and in vivo animal studies on implanted
cells suggest that temperature of at least −4°C is necessary
Figure 7 EUS view of the EUS-RFA probe. EUS, endoscopic
ultrasound; RFA, radiofrequency ablation.
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for destruction of abnormal cells.58–60 Initial cryoinjury
is related to the combination of ice-associated damage
and cellular osmotic shock during the freeze–thaw
process while delayed injury arises from the progressive
failure of microcirculation that leads to vascular stasis
and necrosis.61
Cryotherapy may be performed under real-time guidance
using EUS, CT scan or MRI. This discussion will focus on
EUS-guided cryoablation. A 2 or 3 mm hollow instrument
called a cryoprobe is brought in contact with abnormal
tissue via the working channel of the endoscope. For larger
lesions, multiple probes may be used. Refrigerants are
usually forced through the device under pressure to allow
for quick delivery and to preserve the ﬂexibility of the
cryoprobe. Two cycles of freezing/thawing are performed
with subsequent targeted tissue injury occurring.62
Table 1 Comparison of preneoplastic pancreatic cysts (MCN and IPMN) with pseudocyst
Pseudocyst MCN IPMN
Location Anywhere Primarily body and tail Head, body and tail
EUS features Primarily unilocular, anechoic or contains
debris
Unilocular or oligolocular Multiple cysts communicating with
pancreatic duct, dilated pancreatic
duct
Cystic fluid
analysis
CEA Low High High
Amylase High Usually low but may be high High
Cytology Inflammatory cells Extracellular mucin, mucinous
epithelial
cells and atypical cells may be seen
Extracellular mucin, mucinous
epithelial
cells and atypical cells may be seen
CEA, carcinoembryonic antigen; EUS, endoscopic ultrasound; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm.
Figure 8 Schematic with a brief summary of management of cystic pancreatic lesions. CEA, carcinoembryonic antigen; EUS, endoscopic
ultrasound; FNA, ﬁne needle aspiration; MRCP, MR cholangiopancreatography.
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When applied to the pancreas, this technique is well
known when used in conjunction with brachytherapy or
iodine-125 seed implantation. Iodine-125 is an isotope
which may be implanted at the border of the neoplasm
where temperatures are suboptimal for complete tissue
injury. Seed implantation provides local delivery of γ radi-
ation and induction of apoptosis. Xu et al61 examined 49
patients who underwent iodine-125 seed implantation after
percutaneous cryosurgery and found improvements in
median survival when compared with cryotherapy alone.
Other well-known combination therapies include RFA and
cryogenic cooling using a bipolar cryotherm probe endo-
scopically. Arcidiacono et al62 conducted a cohort study of
16 patients and demonstrated feasibility and safety of this
technology in the pancreas. Endoscopic cryotherapy of
pancreatic cysts is a relatively new technology; thus, efﬁcacy
data are limited.
Complications of cryoablation include those caused by
hypothermic damage to adjacent normal tissue, damage
along the probe track and seeding of neoplastic cells during
probe removal. Incomplete destruction of cells and persist-
ence of neoplastic tissue is possible, particularly within
the border zones where temperatures may be somewhat
warmer than target. In rare cases, perforation and strictures
may occur.62
FUTURE DIRECTIONS
EUS-guided injection of drug-eluting beads
EUS-guided injection of drug-eluting beads loaded with
chemotherapeutic agents such as doxorubicin, mitoxan-
trone, and irinotecan was ﬁrst described in its application
to colorectal liver metastasis. Recently, this technique has
been applied to the pancreas, targeting hepatic metastasis
and peritoneal implants of pancreatic origin.63–65 These
beads are biocompatible polyvinyl-alcohol hydrogel beads
which allow a slow and sustained release of the drug within
a targeted area. Current research demonstrates the utility of
this EUS-guided therapy when applied directly to neo-
plasms of the pancreas in animal models. Karaca et al66
demonstrated the feasibility and safety of EUS-guided
irinotecan-loaded beads in a porcine model. Additional
investigation is needed to further guide use in patients with
pancreatic cystic neoplasms.
EUS-guided neodymium:yttrium aluminum agent laser
ablation
Laser ablation with a neodymium:yttrium aluminum agent
(Nd:YAG) laser is being used in the management of hepato-
cellular carcinoma, liver metastasis in colorectal cancer and
malignant thyroid nodules. These lasers typically emit light
with a wavelength in the infrared spectrum with energy
output sufﬁcient for induction of tissue necrosis. DiMatteo
and colleagues assessed the feasibility of the Nd:YAG laser
for pancreatic tissue necrosis in an animal model. The Nd:
YAG laser (1.064 nm) with an output power of 2 and 3 W
and a total delivery energy of 500 and 1000 J in continu-
ous mode was used in this study. Tissue necrosis of pancre-
atic parenchyma was observed in all animal models on
histological examination. No signiﬁcant technical difﬁcul-
ties or side effects were encountered.67 This technology
remains investigational and future studies of the Nd:YAG
laser are needed prior to implementation.
CONCLUSIONS
Preneoplastic pancreatic cystic lesions are clinically and
pathologically diverse with a variable disease course. Major
management approaches include surgical resection, endo-
scopic techniques, and surveillance. Endoscopic therapeutic
options are vast, minimally invasive, and enable targeted,
individualized therapy for patients who should not
undergo surgical resection. Additional investigation is
needed to evaluate the efﬁcacy and adverse effects of endo-
scopic treatment approaches in place.
Table 1 shows a brief summary of differences between
preneoplastic cystic lesions and pseudocyst.
Below is a simpliﬁed algorithm for management of cystic
lesions of the pancreas with special focus toward preneo-
plastic cystic lesions management (ﬁgure 8).
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